Endocrinology and Metabolism10.3803/enm.2017.32.1.90201732190Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical ResearchHun-Sung Kim, Hyunah Kim, Yoo Jin Jeong, Tong Min Kim, So Jung Yang, Sun Jung Baik, Seung-Hwan Lee, Jae Hyoung Cho, In Young Choi, Kun-Ho Yoon,,
Diabetes Research and Clinical Practice10.1016/0168-8227(87)90147-119873S76P-7-29 Long term effect of the HMG CoA reductase inhibitor (CS-514) on lipid and glucose metabolism of hyperlipidemic diabetics,
Clinical Cardiology10.1002/clc.4960171603200917S4IV-3-IV-10The pharmacology of fluvastatin, a new HMG-CoA reductase inhibitorWilliam R. Garnett,
Clinical Cardiology10.1002/clc.4960240705200124S210-13Newer HMG-CoA reductase inhibitor (statin) therapiesEliot A. Brinton,
Atherosclerosis10.1016/s0021-9150(98)00014-81998138111-24HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials dataJohn R Crouse III, Robert P Byington, Curt D Furberg,
Clinical Therapeutics10.1016/s0149-2918(96)80114-719961820-21C4. Cost-effectiveness trends of HMG-CoA reductase inhibitor therapy in a managed-care populationA. Petitta, R.E. Ward, J.V. Anandan, S.J. Beis, A.M. Johnson,
Clinical Therapeutics10.1016/s0149-2918(00)88280-61999211218-235Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapyMichael B. Bottorff, Joseph P. Yenkowsky, Douglas G. Cave,
British Journal of Clinical Pharmacology10.1111/j.1365-2125.1990.tb03626.x1990292239-243Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.SM Singhvi, HY Pan, RA Morrison, DA Willard,
European Journal of Clinical Pharmacology10.1007/bf014094011991401S15-S18Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductaseH. Y. Pan,,
European Journal of Clinical Pharmacology10.1007/bf03216282199140S1S15-S18Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductaseH. Y. Pan,,